Conditions: Diabetes Diabetes Mellitus, Type 1
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 146
Healthy volunteers: no

Brief summary:
This trial is conducted in Europe. The aim of this research is to assess the safety of continuous treatment with insulin detemir following participation in trial NN304-1689 (NCT00435019) on antibody development.

Detailed description:

Arms:
arm 1: Insulin detemir up to twice daily plus insulin aspart at larger meals, doses are adjusted individually (treatment up to 104 weeks)

Interventions: intervention 1: insulin detemir intervention 2: insulin aspart
Intervention descriptions: intervention 1: Treat-to-target dose titration scheme (individually adjusted), injection s.c. (under the skin), once or twice daily. intervention 2: Treat-to target dose titration scheme (individually adjusted), injection s.c. (under the skin), at larger meals.

Protocol document: